Incyte Reports New Appointments to Its Executive Leadership Team Incyte has announced a series of key leadership appointments within its executive team, signaling a strategic move to strengthen its organizational structure and support long-term growth across research, development, and commercial…
Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan POXEL SA, a biopharmaceutical firm specializing in innovative therapies for serious chronic diseases with metabolic origins, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced a…
Element Science Earns Spot on Fast Company’s 2026 List of the World’s Most Innovative Companies Element Science has earned a place on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, a recognition that highlights organizations driving…
U.S. Food and Drug Administration Approves Updated Label to Enable Faster Thawing of ADSTILADRIN® (nadofaragene firadenovec-vncg) Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an important label update for ADSTILADRIN, introducing a faster and more…
Grifols Advances Plans to Launch IPO for Its U.S. Biopharma Division Grifols has taken a significant strategic step toward reshaping its corporate structure and accelerating long-term growth, as its Strategy Committee has proposed—and its Board of Directors has approved—the potential…
Alnylam Drives Innovation in ATTR-CM Care Through Strategic Collaboration with Viz.ai and Ongoing Support for the American Heart Association Alnylam Pharmaceuticals is spearheading a comprehensive, system-wide initiative aimed at transforming the early detection and management of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM),…
Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid Regeneron Pharmaceuticals and Sanofi have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Dupixent as a treatment for adults suffering…
Eylea™ 8 mg Secures Approval in Japan for Its Third Retinal Disease Indication The Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization in Japan for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for…
Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal Phase 3 VALOR clinical trial evaluating their investigational Lyme disease…
Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has entered into a strategic partnership with Battelle, the world’s largest…
Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the central and peripheral nervous systems, has announced its active participation…
Novo Nordisk A/S: Wegovy® HD (7.2 mg) gains US approval, delivering 20.7% average weight reduction Novo Nordisk has reached another major milestone in the treatment of obesity, announcing that the U.S. Food and Drug Administration (FDA) has granted approval for…